Effect of ketanserin, a new blocking agent of the 5-HT2 receptor, on airway responsiveness in asthma.
Most of the antihypertensive drugs have a liability for adverse effects in asthma. Since there are few available data on the effect of ketanserin, a new antihypertensive drug which is a type-2 serotonin receptor antagonist, on human respiratory function, we have tested whether this drug can modify bronchial hyperresponsiveness to methacholine in asthmatic patients. The protective effect of intravenous ketanserin (0.14 mg/kg) was small, but significant.
Cazzola
M
M
Department of Pulmonary Medicine, A. Cardarelli Hospital, Naples, Italy.
Assogna
G
G
Lucchetti
G
G
Cicchitto
G
G
D'Amato
G
G
D000328:Adult; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D001980:Bronchi / Q000187:drug effects* / Q000503:physiopathology; D001985:Bronchial Provocation Tests / Q000379:methods; D002648:Child; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D007650:Ketanserin / Q000494:pharmacology*; D008297:Male; D016210:Methacholine Chloride; D008688:Methacholine Compounds / Q000008:administration & dosage / Q000037:antagonists & inhibitors* / Q000276:immunology; D012702:Serotonin Antagonists / Q000494:pharmacology
D008688:Methacholine Compounds; D012702:Serotonin Antagonists; D016210:Methacholine Chloride; D007650:Ketanserin